KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) soaring 30% in early morning trading, adding to their 20% rise after Friday’s news that the company appointed Martin Shkreli as …
In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price …